Compare EE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | LXRX |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.6M |
| IPO Year | 2022 | 2000 |
| Metric | EE | LXRX |
|---|---|---|
| Price | $39.35 | $2.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $39.20 | $4.15 |
| AVG Volume (30 Days) | 324.2K | ★ 2.8M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | 0.79 | ★ 77.78 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $1,228,263,000.00 | $49,803,000.00 |
| Revenue This Year | $23.59 | N/A |
| Revenue Next Year | $24.37 | N/A |
| P/E Ratio | $52.48 | ★ N/A |
| Revenue Growth | 44.26 | ★ 60.24 |
| 52 Week Low | $23.23 | $1.03 |
| 52 Week High | $43.18 | $2.68 |
| Indicator | EE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 48.99 |
| Support Level | $32.03 | $2.05 |
| Resistance Level | $40.00 | $2.50 |
| Average True Range (ATR) | 1.47 | 0.16 |
| MACD | 0.27 | -0.02 |
| Stochastic Oscillator | 89.59 | 61.61 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.